Larvol Delta - MesoPher-Cell-Therapy-Increases-2Year-RFS-Rate-in-Resected-Pancreatic-Cancer-by-50-Amphera-Announces-Publication-of-Phase-II-Results-in-Journal-of-Clinical-Oncology-and-Orphan-Designation-Granted-by-FDA-amp-EMA

MesoPher (autologous dendritic cell vaccine) - Erasmus MC, Amphera

https://www.businesswire.com/news/home/20240924023419/en/MesoPher-Cell-Therapy-Increases-2-Year-RFS-Rate-in-Resected-Pancreatic-Cancer-by-50-Amphera-Announces-Publication-of-Phase-II-Results-in-Journal-of-Clinical-Oncology-and-Orphan-Designation-Granted-by-FDA-EMA

Sep 25, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next